2025 China Anti-Infective Vaccines Market Revenue Opportunities Report
Description
The 2025 China Anti-Infective Vaccines Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Infective Vaccines Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the anti-infective vaccines market in China include GlaxoSmithKline (GSK), Sanofi, Merck & Co., and Pfizer. GSK holds about 20-25% market share with a broad vaccine portfolio including RSV and shingles vaccines, despite recent sales declines linked to price competition and regulatory challenges. Sanofi focuses on vaccines for various infectious diseases with a strong R&D pipeline, holding about 15-20% market share. Merck leverages its recently approved Capvaxive pneumococcal vaccine to challenge Pfizer’s Prevnar 20, holding 12-15% share. Pfizer leads the pneumococcal vaccine segment with Prevnar 20, with a 10-12% market share supported by robust global distribution and vaccine coverage expansion.
These multinational companies face increasing competition from Chinese firms like Wantai Biopharm and Changchun BCHT Biotechnology, which offer lower-cost, high-volume HPV and shingles vaccines, disrupting market dynamics. Regulatory scrutiny, anti-corruption measures, and China's prioritization of domestic manufacturers have pressured foreign companies to adapt their strategies amid a cooling economic environment. China National Biotec Group (CNBG), the largest state-owned bio-pharmaceutical in China, also plays a critical role with extensive vaccine production capacity, supplying over 80% of vaccines for China's Expanded Program on Immunization (EPI) and engaging in collaborations to improve global vaccine R&D and access.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Infective Vaccines Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the anti-infective vaccines market in China include GlaxoSmithKline (GSK), Sanofi, Merck & Co., and Pfizer. GSK holds about 20-25% market share with a broad vaccine portfolio including RSV and shingles vaccines, despite recent sales declines linked to price competition and regulatory challenges. Sanofi focuses on vaccines for various infectious diseases with a strong R&D pipeline, holding about 15-20% market share. Merck leverages its recently approved Capvaxive pneumococcal vaccine to challenge Pfizer’s Prevnar 20, holding 12-15% share. Pfizer leads the pneumococcal vaccine segment with Prevnar 20, with a 10-12% market share supported by robust global distribution and vaccine coverage expansion.
These multinational companies face increasing competition from Chinese firms like Wantai Biopharm and Changchun BCHT Biotechnology, which offer lower-cost, high-volume HPV and shingles vaccines, disrupting market dynamics. Regulatory scrutiny, anti-corruption measures, and China's prioritization of domestic manufacturers have pressured foreign companies to adapt their strategies amid a cooling economic environment. China National Biotec Group (CNBG), the largest state-owned bio-pharmaceutical in China, also plays a critical role with extensive vaccine production capacity, supplying over 80% of vaccines for China's Expanded Program on Immunization (EPI) and engaging in collaborations to improve global vaccine R&D and access.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
